Compare Enveric Biosciences Inc (ENVB) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares International Treasury Bond ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B). The key difference: iShares International Treasury Bond ETF is far larger — about 191.2× Enveric Biosciences Inc's market cap, and iShares International Treasury Bond ETF is more actively traded (693,740 versus 64,867). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares International Treasury Bond ETF for 92 Days on average.
| ENVB | IGOV | |
|---|---|---|
Market Cap | $6.80M | $1.30B |
Volume | 64,867 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $42.99 |
52-Week Low | $1.27 | $39.65 |
Typical Hold Time | 14 Days | 92 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
IGOV trades at $39.70, down 0.48% with a bearish technical outlook as moving averages signal selling pressure. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental assessment. Recent news highlights rising global bond yields, which may impact interest-rate sensitive sectors. The stock shows neutral oscillator signals with RSI levels near oversold territory at 30-37.
Investment outlook remains cautious due to incomplete financial data and bearish technical indicators. Rising Treasury yields pose macroeconomic headwinds, while the absence of valuation metrics complicates risk-reward analysis. Investors require updated SEC filings and earnings reports to properly evaluate the company's financial health and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
